Notably, the PDGFRA-targeting agent avapritinib has been shown to enhance the sensitivity of HCC cells to lenvatinib across cellular assays, patient-derived organoid cultures, and diverse animal models. The gene discussed is PDGFRA; the disease is hepatocellular carcinoma.